Latest Rosuvastatin Stories
NEW YORK, Jan.
Healthy people may derive no benefit from taking cholesterol-lowering statins, according to a review of previous studies.
WILMINGTON, Del., Dec. 22, 2010 /PRNewswire/ -- AstraZeneca (NYSE: AZN) announced today that it has notified Abbott that it will discontinue the development of CERTRIAD(TM) (rosuvastatin calcium and fenofibric acid), which was being investigated for the treatment of mixed dyslipidemia.
ABBOTT PARK, Ill., Dec. 22, 2010 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today that Abbott and AstraZeneca will discontinue their joint collaboration for the development of CERTRIAD(TM) (rosuvastatin / fenofibric acid delayed release) Capsules.
HAIKOU CITY, China, Dec. 6, 2010 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc.
Patent filing is based on synergistic findings suggesting enhanced plaque management with RVX-208 in combination with statins TSX Exchange Symbol: RVX CALGARY, Nov. 29 /PRNewswire-FirstCall/ - Resverlogix Corp.
BURLINGTON, Mass., Nov.
Widely prescribed for their cholesterol-lowering properties, recent clinical research indicates that statins can produce a second, significant health benefit: lowering the risk of severe bacterial infections such as pneumonia and sepsis.
NEW YORK, Oct.
MORRISTOWN, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed a new drug application under Section 505(b)(2) of the Federal Food and Drug Cosmetic Act (FFDCA) with the U.S.